行情

KMPH

KMPH

KemPharm
NASDAQ

实时行情|Nasdaq Last Sale

8.67
-0.15
-1.75%
交易中 11:08 09/16 EDT
开盘
8.77
昨收
8.82
最高
8.77
最低
8.56
成交量
11.40万
成交额
--
52周最高
22.08
52周最低
5.08
市值
3.05亿
市盈率(TTM)
-1.8798
分时
5日
1月
3月
1年
5年
KemPharm 将出席 Virtual HC Wainwright 第 23 届年度全球投资会议
CELEBRATION, Fla., Sept. 09, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and Chief Exec...
GlobeNewswire · 09/09 11:30
SoFi Technologies, Cricut, FIGS among premarket losers' pack
ContextLogic (NASDAQ:WISH) -27% on Q2 earnings release Cricut (NASDAQ:CRCT) -22% on Q2 earnings release Rigel Pharmaceuticals (NASDAQ:RIGL) -18% after FDA declines to approve fostamatinib COVID-19 EUA LifeMD (NASDAQ:LFMD) -13% on Q2 earnings release Sierra...
Seekingalpha · 08/13 12:54
KemPharm Q2 每股收益 0.18 美元低于 0.22 美元的估计,销售额 1200 万美元低于 1210 万美元的估计
KemPharm (NASDAQ:KMPH) reported quarterly earnings of $0.18 per share which missed the analyst consensus estimate of $0.22 by 18.18 percent. This is a 1700 percent increase over earnings of $0.01 per share from the same
Benzinga · 08/12 20:56
KemPharm 报告 2021 年第二季度财务业绩
Corporate and Regulatory Highlights U.S. Commercial Launch of AZSTARYS™ Initiated on July 21, 2021Serdexmethylphenidate (SDX) Classified as a Schedule IV Controlled Substance by the DEAAnnounced Orange Book Listing for Six Patents Covering SDX and Confirma...
GlobeNewswire · 08/12 20:05
-- 盈利快报 (KMPH) KEMPHARM 报告第二季度收入 1200 万美元
MT Newswires · 08/12 16:32
预计 2021 年 8 月 12 日的收益
  Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
Benzinga · 08/12 08:14
每日生物技术脉搏:Arcturus 因 COVID-19 疫苗更新而飙升,默克的 Keytruda 有望实现更多标签扩展,Eliem 首次亮相
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9)
Benzinga · 08/10 11:55
生物技术的未来一周(8 月 8 日至 14 日):Jazz Pharma FDA 的决定、收益泛滥和 IPO 成为焦点
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the...
Benzinga · 08/08 14:03
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解KMPH最新的财务预测,通过KMPH每股收益,每股净资产,每股现金流等数据分析KemPharm近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测KMPH价格均价为19.00,最高价位28.00,最低价为10.00。
EPS
机构持股
总机构数: 89
机构持股: 1,267.03万
持股比例: 36.04%
总股本: 3,515.37万
类型机构数股数
增持
11
326.98万
建仓
36
276.64万
减持
9
20.57万
平仓
17
53.86万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.52%
制药与医学研究
-0.69%
高管信息
Chairman/President/Chief Executive Officer/Director
Travis Mickle
Chief Financial Officer/Treasurer/Secretary
R. LaDuane Clifton
Executive Vice President
Sven Guenther
Vice President/Controller
Timothy Sangiovanni
Lead Director/Independent Director
Richard Pascoe
Director
Tamara Seymour
Independent Director
Matthew Plooster
Independent Director
Joseph Saluri
Independent Director
David Tierney
暂无数据
KMPH 简况
KemPharm, Inc.是一家临床阶段的专业制药公司。该公司从事前体药物的发现与开发业务。该公司使用配体激活疗法(LAT)平台技术制备前体药物。该公司候选产品KP201/APAP由与醋氨酚(APAP)结合的氢可酮的前药KP201组成。该公司正在开发立即释放(IR)候选产品KP201/APAP,用于短期或不超过14天管理急性疼痛。该公司设计具备遏制滥用特性的KP201 /APAP,解决美国阿片滥用的流行病。该公司还专注于开发用于疼痛和注意缺陷障碍(ADHD)的其他前药候选产品。该公司产品包括KP201/IR(无APAP)、KP511/ER、KP415、KP606/IR和KP746。

微牛提供KemPharm Inc(NASDAQ-KMPH)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的KMPH股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易KMPH股票基本功能。